Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04286113 · ClinicalTrials.gov registry record · NA
PREDHICT: Precision Recruitment and Engagement of Diabetics and Hypertensives in Clinical Studies
A NA study of Cardiovascular Disease, sponsored by NYU Langone Health.
- Completed
- Registry status
- NA
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT04286113: Completed NA study of Cardiovascular Disease, sponsored by NYU Langone Health.
NCT04286113 is a NA study of Cardiovascular Disease that has completed, run by NYU Langone Health. The registered enrollment target is 100 participants, below the 2,697-participant average among 137 other Cardiovascular Disease trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04286113, a NA study of Cardiovascular Disease, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
For the sub-study, this digital navigation tool will both inform/educate, engage, support, and navigate participants and providers through the process of clinical trial participation via personalization (data profiling, adaptive and customized messaging, and tailored digital navigation) in a sample of 100 participants with diabetes and hypertension.
Primary Outcome
Will show that one-size-fits-all versus personalization leads to greater adherence. Adherence will be based on whether the subject met the daily and weekly behavior recommendations.
Conditions Studied
Interventions
- BEHAVIORAL control group
- BEHAVIORAL Lifestyle management
Study Locations (1)
New York
- NYU Langone - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2020-10-20 |
| Est. Completion | 2021-10-27 |
| Phase | NA |
What the finished NCT04286113 record still lists
NCT04286113 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 2,697-participant average among 137 other Cardiovascular Disease trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Cardiovascular Disease appearing as the primary indexed condition, and to 2 interventions - of which control group is the first listed.
NCT04286113 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT04286113 about?
NCT04286113 is a clinical study titled "PREDHICT: Precision Recruitment and Engagement of Diabetics and Hypertensives in Clinical Studies". For the sub-study, this digital navigation tool will both inform/educate, engage, support, and navigate participants and providers through the process of clinical trial participation via personalization (data profiling, adaptive and customized messaging, and tailored digital navigation) in a sample ...
What is the current status of trial NCT04286113?
This trial is currently completed. It is a NA study. The enrollment target is 100 participants. The study started on 2020-10-20. Estimated completion is 2021-10-27.
What conditions does trial NCT04286113 study?
This clinical trial studies the following conditions: Cardiovascular Disease.
What interventions are being tested in trial NCT04286113?
The interventions under investigation include: control group (BEHAVIORAL), Lifestyle management (BEHAVIORAL).
Who is sponsoring clinical trial NCT04286113?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04286113 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04286113's enrollment target sits among peer trials
100 76th of 137 higher than 59 of 137 other Cardiovascular Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiovascular Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients
RECRUITING · NA
-
A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors
RECRUITING · NA
-
Gauging Outcomes of Total Milk Ingestion on Lipid and gControl
RECRUITING · NA
-
Determining the Benefits of Exercise on Cardiovascular Risk in PTSD
RECRUITING · NA
-
Century Trial, a Randomized Lifestyle Modification Study for Management of Stable Coronary Artery Disease
ACTIVE NOT RECRUITING · NA
-
Nitric Oxide Bioavailability and Early Life Stress (NO-Stress)
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI